From Medscape Dermatology

Coverage from the

American Academy of Dermatology (AAD) 2022 Annual Meeting

March 25 - 29, 2022; Hybrid/Boston, Massachusetts

March 25 - 29, 2022 Hybrid/Boston, Massachusetts
  • AAD 2022 JAK Inhibitors Improve Vitiligo, Trials Show Separate clinical trials of ruxolitinib and ritlecitinib showed both therapies resulted in significant repigmentation in patients with vitiligo.
  • AAD 2022 For Pemphigus, Rituximab Is First Line, Expert Says Lower healthcare costs and efficacy put rituximab ahead of traditional treatments, such as corticosteroids, doxycycline, and immunomodulators, for the autoimmune blistering disease, an expert said.
  • AAD 2022 Cellulitis Care Costly From Misdiagnosis, Needless Hospitalizations The skin infection cellulitis is a major and growing consumer of healthcare resources, but there are large potential cost savings for each step in care management, including involving dermatologists.

Conference News

Popular News from AAD VMX 2021

Medscape Dermatology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.



Previous Coverage

Related Resources